{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008652","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.787558+00:00","generated_at":"2026-06-15T09:17:11.501483+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M","bullets":["Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).","Cash, cash equivalents and marketable securities $273.3M as of March 31, 2023; plus $25M Novartis option payment received after quarter.","Neurocrine Biosciences strategic collaboration: $175M upfront, up to $1.5B development milestones, $2.7B commercial milestones.","Novartis exercised options for novel TRACER capsids: $25M payment, up to $600M milestones and royalties.","Anti-tau antibody program VY-TAU01; IND filing on track for H1 2024. SOD1 program lead candidate now expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008652","json":"https://secwatch.observer/filing/0001558370-23-008652.json","markdown":"https://secwatch.observer/filing/0001558370-23-008652.md","text":"https://secwatch.observer/filing/0001558370-23-008652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/0001558370-23-008652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/vygr-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:17:11.501483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bab70cf053ce83590233cd447fc5f197e9e953bd","claim":"Voyager Therapeutics, Inc. reported first quarter 2023 results: revenue $150.5 million, net income $124.0 million.","evidence_excerpt":"In January 2023, Grace E. Colón, Ph.D., also joined the Board of Directors. ​ First Quarter 2023 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $150.5 million for the first quarter of 2023, compared to $0.7 million for the same period in 2022. The increase was primarily due to revenue recognized during the first quarter of 2023 on the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/0001558370-23-008652-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$150.5 million"},{"label":"Net income","value":"$124.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}